• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

13 Potential Blockbuster Drugs and Gamechangers to Watch in 2024

by Fred Pennic 01/12/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

– Clarivate Plc, a provider of trusted information and insights, today unveiled its highly anticipated 2024 Drugs to Watch report, shining a spotlight on 13 cutting-edge therapeutics poised to revolutionize healthcare in the coming year.

– These promising drugs span a diverse range of conditions, from debilitating diseases like sickle cell anemia and multiple myeloma to common ailments like chronic obstructive pulmonary disease (COPD) and age-related macular degeneration (AMD).

Top 13 Drugs to Watch in 2024

The 2024 Drugs to Watch, are:

– Aflibercept (high dose): Less frequent injections for treating AMD, DME, and DR, potentially reducing treatment burden.

– Budesonide (TARPEYO®/Kinpeygo®/Nefecon): Improved treatment for primary immunoglobulin A (IgA) nephropathy with better safety profile than conventional corticosteroids.

– Datopotamab deruxtecan (Dato-DXd): Potential best-in-class TROP2-targeted ADC for breast cancer and non-small cell lung cancer.

– Efanesoctocog alfa (ALTUVIIIO™/BIVV001): First once-weekly factor VIII replacement therapy for hemophilia A, offering improved convenience.

– Ensifentrine (RPL554): First inhaled dual PDE3 and PDE4 inhibitor for COPD, potentially reducing exacerbations with fewer side effects.

– Exagamglogene autotemcel (CASGEVY™ /exa-cel) and lovotibeglogene autotemcel (LYFGENIA™/lovo-cel): Groundbreaking gene-editing therapies for sickle cell disease and beta-thalassemia, offering potential cures.

– Mirikizumab (Omvoh™/ LY-3074828): First-in-class therapy for ulcerative colitis and potential third-in-class option for Crohn’s disease.

– Niraparib + abiraterone acetate (AKEEGA™): First dual-action tablet for deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer.

– RSVpreF (ABRYSVO™/PF-06928316) and RSVpreF3 (AREXVY/GSK-3844766A): First RSV vaccines for infants and older adults, addressing a major public health concern.

– Talquetamab (TALVEY™): First-in-class bispecific antibody for multiple myeloma, offering a new treatment option for heavily pretreated patients.

– Zolbetuximab (IMAB362): First-in-class claudin 18.2 inhibitor for HER2-negative metastatic gastric or gastroesophageal junction adenocarcinoma, addressing a significant unmet need.

Beyond the Drugs

The report also highlights the growing influence of new technologies like CRISPR-Cas9 gene editing and AI/ML in the drug development process. These tools hold immense potential to accelerate innovation and bring life-saving therapies to patients faster.

“This year’s Drugs to Watch report showcases the incredible advancements taking place across the pharmaceutical landscape,” says Mike Ward, Global Head of Thought Leadership, Life Sciences and Healthcare at Clarivate. “New modalities like antibody drug conjugates and AI-powered tools are fueling medical breakthroughs, offering hope to patients with previously unmet needs.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

 Selecting the Right EMR: A Practical Guide to Streamlining Your Practice and Enhancing Patient Care

Selecting the Right EMR: A Practical Guide to Streamlining Your Practice and Enhancing Patient Care

Featured Interview

Virta Health CEO: GLP-1s Didn’t Kill Weight Watchers, Its Broken Model Did

Most-Read

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Health IT Sector Navigates Policy Turbulence with Resilient M&A

Health IT’s New Chapter: IPOs Return, Resilient M&A, Valuations Rise in 1H 2025

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

CMS Finalizes New Interoperability and Prior Authorization Rule

CMS Proposes 2026 Physician Fee Schedule Rule: Boosting Primary Care, Cutting Waste, and Modernizing Payments

Beyond SaaS: How Agent as a Service is Transforming Healthcare Automation

Beyond SaaS: How Agent as a Service is Transforming Healthcare Automation

New Strategies Needed: No Surprises Act and the Challenges for Payors with Provider Data Inaccuracies

Samsung Acquires Xealth to Accelerate Connected Care Vision

Samsung Acquires Xealth to Accelerate Connected Care Vision

AI Dominates Digital Health Investment in First Half of 2025

Rock Health Report: AI Dominates Digital Health Investment in First Half of 2025

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |